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Abstract
Background: The significance of high systolic and diastolic blood pressure remains controversial. We assessed the
differences in prevalence of hypertension and its subtypes according to the different hypertension diagnostic
criteria embodied by the 2017 American College of Cardiology/American Heart Association (2017 ACC/AHA) and
2018 Korean Society of Hypertension (2018 KSH) guidelines.
Methods: We used the 2007–2017 Korea National Health and Nutrition Examination Survey (KNHANES) data to
calculate guideline-specific hypertension prevalence among untreated, adult participants. By the 2017 ACC/AHA
guideline, a mean SBP ≥130 mmHg, DBP ≥80 mmHg, or currently using antihypertensive medications were
considered to have hypertension. Isolated diastolic hypertension (IDH) was defined as DBP ≥80 mmHg and SBP <
130 mmHg, isolated systolic hypertension (ISH) as SBP ≥130 mmHg and DBP <80 mmHg, and systolic diastolic
hypertension (SDH) as SBP ≥130 mmHg and DBP ≥80 mmHg. In a similar manner, by the 2018 KSH guideline, all
hypertension and its subtype prevalence were calculated using the 140/90 mmHg cutoff. The two versions of all
hypertension and its corresponding subtype prevalence were calculated among all study participants and
separately by sex and age then compared via analysis of variance.
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Results: The prevalence of all hypertension increased from 25.9% (95% confidence interval (CI) 25.4–26.5) defined
by the 2018 KSH guideline to 46.3% (95% CI 45.6–46.9) classified by the 2017 ACC/AHA guideline. Such increase
was primarily manifested through substantial increase in IDH prevalence, from 5.2% (95% CI 4.9–5.4) defined by the
2018 KSH guideline to 17.9% (95% CI 17.4–18.3) defined by the 2017 ACC/AHA guideline, and was most notably
observed in young age groups, 30-49 years. ISH prevalence showed minimal differences. SDH prevalence
moderately increased from 3.5% (95% CI 3.3–3.7) defined by the 2018 KSH guideline to 11.1% (95% CI 10.7–11.4)
defined by the 2017 ACC/AHA guideline, achieved primarily among participants aged 50 years or above.
Conclusions: Changes in each subtype prevalence made differential contribution to additionally classified
hypertension cases by the 2017 ACC/AHA guideline. Future studies should investigate the diastolic-associated
cardiovascular risks and benefits of its long-term primary prevention in the young population.
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Introduction
High blood pressure (BP) is a major yet modifiable risk
factor for cardiovascular diseases (CVD) [1–4]. Despite its
established causal and exacerbating role in a wide array of
chronic diseases, high BP remains a global concern, con-
tributing to substantial morbidity and mortality [5–8].
Clinical and epidemiological studies have demonstrated
continuous association between high BP and CVD risk in
all sex, race, and age [9–11]. However, considering the
different types and distributions of CVD risk factors across
different demographics [12], previous studies have re-
ported diverging findings regarding the significance of ele-
vated systolic and diastolic blood pressure (SBP & DBP)
[13–15]. One meta-analysis showed that each 20-mmHg
SBP or 10-mmHg DBP increase was associated with ap-
proximately a two-fold increased risk for stroke and
vascular-related mortality without definite lower threshold
[9]. Yet, a recent analysis of the Korean national health in-
surance data indicated while elevated SBP remains an in-
dependent and strong predictor of future CVD, DBP
showed SBP-dependent indication [16]. Accounting for di-
verging claims on role of elevated SBP versus DBP, it
deems essential to evaluate the nation’s recent prevalence
of hypertension, specifically by its subtypes.
With continued effort to provide optimal prevention and
management guideline on hypertension, the 2017 American
College of Cardiology/ American Heart Association Guide-
line for the Prevention, Detection, Evaluation, and Manage-
ment of High Blood Pressure in Adults (2017 ACC/AHA
guideline) [17] have adopted a markedly lower BP cri-
teria in defining hypertension, from the Seventh Report
of the Joint National Committee on Prevention, Detec-
tion, Evaluation and Treatment of High Blood Pressure
(JNC 7) [18]’s previous 140/90 mmHg to 130/80 mmHg.
Despite the diagnostic criteria remained 140/90 mmHg,
the 2018 Korean Society of Hypertension Guidelines
for the Management of Hypertension (2018 KSH guide-
line) [19] considered recommendation for pharmaco-
logical treatment in prehypertension (130–139 mmHg/
80–89 mmHg) individuals with high-risk for atheroscler-
otic cardiovascular diseases (ASCVD), such as chronic kid-
ney disease (CKD) or diabetes mellitus (DM) comorbidity.
Timely assessment of pervasiveness of hypertension and
its management across the entire lifespan are crucial in pre-
venting further adverse health outcomes at individual level
and conserving substantial healthcare resources at national
level. With implementation of the new diagnostic criteria in
2017 ACC/AHA guideline and increasing emphasis on
future ASCVD risk level observed in the most recent
Korean guideline, our objective was to assess the difference
in prevalence of hypertension and its subtypes by sex and
age groups according to the two aforementioned guidelines.
Specifically, by investigating which subtype and population
characteristics are primarily responsible for overall hyper-
tension prevalence difference, we aimed to provide frame-
work in detecting potential target group that will benefit
from early lifestyle and/or pharmaceutical interventions in
contemporary Korean population.
Methods
Study population
This study analyzed data from the Korea National Health
and Nutrition Examination Survey (KNHANES) conducted
between 2007 and 2017. The KNHANES is an ongoing sur-
veillance system in the Republic of Korea that assesses
current health status and distributions of chronic diseases
risk factors [20]. It collects detailed information on demo-
graphics, disease history, health behaviors, and healthcare
utilization, nutrition and provides detailed anthropometric,
blood, and urinal profiles from on-site health examin-
ation [20]. To produce unbiased cross-sectional esti-
mates of the Korean population, it uses complex,
multi-stage probability sample design. Sample weights
are constructed to account for non-response and post-
stratification [20]. The details of the KNHANES is
published elsewhere [20, 21]. The KNHANES IV-VII
were administered by the Korea Center for Disease
Control and Prevention and approved by the
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Institutional Review Board (2007–02-CON-04-P, 2008-
04EXP-01-C, 2009-01CON-03-2C, 2010-02CON-21-C,
2011-02CON-06-C, 2012-01EXP-01-2C, 2013-07CON-
03-4C, 2013-12EXP-03-5C, 2015-01-02-6C). In the
present study, among 89,630 participants, 21,473 child/
adolescent participants under the age of 20 were excluded.
Then, 4853 participants with missing BP measurements or
information on antihypertensive medication intake were
further excluded. Of the remaining 63,304 participants,
3537 participants without measurement on key covariates
required to calculate ASCVD risk score, including cigarette
smoking history, DM prevalence, and total and high-
density lipoprotein cholesterols were additionally excluded.
Consequently, 59,767 participants (26,920 male and 36,384
female) were included for the final analyses.
Blood pressure measurement and definition of
hypertension and its subtypes
BP was measured using a standard mercury sphygmoman-
ometer (Baumanometer Wall Unit 33(0850); Baum Co.,
Inc., Copiague, NY, USA). Participants sat in a comfort-
able position after they had rested for at least 5 min and
had refrained from smoking 30min prior to the measure-
ment. BP was measured on three consecutive occasions in
a standardized environment, free of disturbances, at 1-min
intervals. The average of the second and the third mea-
surements was adopted for the data analysis. Information
regarding hypertension treatment was obtained via self-
report. Participants who used antihypertensive medication
for 20 or more days per month were classified as the
treated group. Hypertension prevalence was defined ac-
cording to the 2017 ACC/AHA as well as the 2018 KSH
guidelines among total study participants.
According to the 2017 ACC/AHA guideline, partici-
pants with SBP ≥130mmHg, DBP ≥80mmHg, or current
antihypertensive medication were considered to have
hypertension. Then, among participants with untreated
hypertension, three types of hypertension subtypes were
operationally defined and assessed: isolated diastolic
hypertension (IDH) was defined as SBP <130mmHg and
DBP ≥80mmHg; isolated systolic hypertension (ISH) was
defined as SBP ≥130mmHg and DBP <80 mmHg; systolic
diastolic hypertension (SDH) was defined as SBP ≥130
mmHg and DBP ≥80mmHg. Likewise, according to the
2018 KSH guideline, hypertension was defined as SBP
≥140mmHg, DBP ≥90mmHg, or current intake of antihy-
pertensive medications. Again, we further stratified the
untreated individuals into one of the following subtypes:
IDH, defined as SBP <140mmHg and DBP ≥90mmHg,
ISH defined as SBP ≥140mmHg and DBP <90 mmHg,
and SDH as SBP ≥140mmHg and DBP ≥90mmHg.
The guideline-specific prevalence of all hypertension
and its corresponding subtypes were calculated among
all study participants combined and separately by sex
and decile age groups. All presented statistics are
weighted accordingly to account for contemporary Ko-
rean population structure.
Covariates
By cross-referencing with government issued identification
code, we ensured participants’ biological age in years, then
categorized into: 20–29 years, 30–39 years, 40–49 years,
50–59 years, 60–69 years, 70–79 years, and 80 years or
above. Using validated questionnaire, trained interviewee
collected information on the following. Physical activity was
assessed by fulfillment of “sufficient activity” by the Korean
version of the International Physical Activity Questionnaire
standard [22]. Alcohol consumption and cigarette smoking
status was divided into current-, previous-, and non- by the
time of survey administration. History of chronic diseases,
including formal diagnosis by medical doctor and treatment
status was also collected.
The health examination obtained participants’ body
weight and height to the nearest 0.1 kg and 0.1 cm, re-
spectively, while wearing light clothing without shoes.
Body mass index was then calculated as the ratio of
weight in kilograms to height in squared meters. For
chemistry tests, cholesterol and fasting glucose concen-
trations were enzymatically assessed via Hitachi Auto-
matic Analyzer 7600 (Hitachi, Tokyo, Japan) in 2007 and
COBAS 8000 C702 (Roche Diagnostics System, Rotk-
reuz, Switzerland) onwards. In accordance with the 2019
Clinical Practice Guidelines for Type 2 Diabetes Mellitus
in Korea [23] 8-h fasting plasma blood glucose ≥126
mg/dL, glycated hemoglobin level ≥6.5%, or current DM
treatment was considered prevalent DM. From 8-h fast-
ing cholesterols and 12-h fasting triglyceride, we referred
to the Korean Society of Lipid and Atherosclerosis’ 2018
Guidelines for The Management of Dyslipidemia [24]:
hypercholesterolemia referred to total cholesterol ≥240
mg/dL; hypertriglyceridemia referred to triglyceride
≥200 mg/dL; hypo-high-density-lipoprotein-cholesterole-
mia referred to high-density lipoprotein cholesterol <40
mg/dL; or current lipid-lowering treatment. Using serum
creatinine concentration, glomerular filtration rate was
derived from the Chronic Kidney Disease-Epidemiology
Collaboration [25] equation. Based on Kidney Disease
Improving Global Outcomes 2018 guideline [26], glom-
erular filtration rate <60 mL/min/1.73 m2 was considered
prevalent CKD. To assess whether differences in hyper-
tension prevalence are accompanied by differences in
predicted cardiovascular risk, we yielded 10-year ASCVD
risk scores that were derived from two different algo-
rithms: 1) 2013 ACC/AHA Pooled Cohort Equation
(PCE) [27]; 2) Korean Risk Prediction Model (KRPM)
[28]. Quality of the survey was controlled by trained
personnel using calibrated equipment and strictly adher-
ing to standardized protocols.
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Statistical analyses
General characteristics of the study population were
reported as weighted frequency or mean and its corre-
sponding 95% confidence interval (CI). Differences in
participant characteristics across stages of hypertension
and by the hypertension subtypes were compared via
analysis of variance. All hypertension prevalence calcu-
lated by dividing the number of pertinent (subtype) cases
by the total study population. The same was done after
stratifying the participants by sex and age groups. All
statistical tests were two-sided, and statistical signifi-
cance was set at a p-value <0.05. All analyses were
performed using SAS version 9.4 (SAS Institute Inc.,
Cary, NC).
Results
Participant characteristics
Table 1 presents general characteristics of participants
by BP classification according to the 2017 ACC/AHA
and 2018 KSH guidelines, separately. The treated indi-
viduals are allocated in a separate group. Regardless of
the referred guideline, participants classified into higher
stage hypertension were older with higher proportion of
male sex. In general, they also had higher body mass
index, glycemic and lipid indices and more reduced kid-
ney function. When examining health-related lifestyle,
participants with higher BP were more likely to be
current smoker and drinker yet less likely to fulfill regu-
lar physical activity. Altogether, participants with higher
BP embodied higher predicted 10-year ASCVD risk
score by both the PCE (2.0% in normal BP vs. 19.1% in
stage 2 hypertension by 2018 KSH guideline and 16.4%
by 2017 ACC/AHA guideline) and KRPM (2.0% in nor-
mal BP vs. 15.5% in stage 2 hypertension by 2018 KSH
guideline and 12.2% by 2017 ACC/AHA guideline),
respectively.
Prevalence of hypertension and its subtypes
Sex- and age-stratified all hypertension and subtype
prevalence are illustrated in Table 2 and Figs. 1, 2 and 3.
In general, the degree of difference varied in each sub-
type by the guideline used for BP classification. Overall,
the prevalence of all hypertension increased from 25.9%
(95% CI 25.4–26.5) defined by the 2018 KSH guideline
to 46.3% (95% CI 45.6–46.9) classified by the 2017 ACC/
AHA guideline, the latter yielding additional 20.3%. The
addendum was most distinguished in age group 40–49
years (23.9%, 95% CI 23.0–24.8); in sex-stratified analysis,
such trend was retained in male (30.1%, 95% CI 28.6–
31.5) whereas observed in older female, 50–59 years
(20.5%, 95% CI 19.3–21.7). Yet, in both sex, the additional
inclusion of newly diagnosed hypertension by the 2017
ACC/AHA guideline primarily came from younger partic-
ipants. Else, 14.7% (95% CI 14.3–15.1) of the participants
were currently receiving pharmaceutical treatment for
hypertension regardless of the guideline referred to.
When examining individual subtype of hypertension,
there were diverging magnitude and direction of changes
in prevalence calculated based on the two guidelines.
The most marked change stemmed from increased
prevalence of IDH, from 5.2% defined by the 2018 KSH
guideline to 17.9% defined by the 2017 ACC/AHA
guideline. Specifically, the dramatic increase was ob-
served in young age groups 30–49 years (14.9% in age
30–39 years; 15.2% in age 40–49 years). When further
stratifying by sex, young males of age 20–29 years also
contributed to substantial increase, whereas older fe-
males in their fifth decade underwent considerable in-
crease in IDH prevalence. In contrast, the changes in
ISH prevalence were notably miniscule. The overall dif-
ference between the 2018 KSH and 2017 ACC/AHA
guideline was 0.1%, which was relatively evenly distrib-
uted across all age groups.. However, interestingly, in
middle-aged population, the prevalence of ISH actually
decreased when defined by the 2017 ACC/AHA guide-
line; in male, such reductions were observed in age
groups 40–49 years by − 0.1%, 50–59 years by − 1.4%,
and 60–69 years by − 0.3% in female, in age groups 40–
49 years by − 0.2% and 50–59 years by − 0.7%. Lastly,
the prevalence of SDH increased from 3.5% (95% CI
3.3–3.7) defined by the 2018 KSH guideline to 11.1% de-
fined by the 2017 ACC/AHA guideline, yielding 7.6% in-
crease in total study population. The difference
acclimated to its zenith 11.4% in 50–59 years male and
9.9% in 60–69 years female. The largest sex-discrepancy
in SDH prevalence shift was observed in the youngest
group, where the 2017 ACC/AHA guideline extended
additional 6.3% male whereas only 0.8% female.
Additional hypertension prevalence according to the
2017 ACC/AHA guideline
Table 3, Additional file 1: Table S1 and Additional file 1:
Table S2 describe a subset of 11,336 individuals who are
additionally categorized into hypertension group accord-
ing to the 2017 ACC/AHA guideline from the prehyper-
tension group by the 2018 KSH guideline—referred to as
the difference of the two guidelines. Of those, 8067 indi-
viduals (76.2%) are qualified as hypertension status as
IDH, 1289 individuals (8.2%) as ISH, and 1980 individ-
uals (15.6%) as SDH. Compared to those newly classified
as hypertension group as ISH or SDH subtype, the IDH
counterpart encompassed significantly higher proportion
of young age groups and male sex (p <0.0001). More-
over, it had higher proportion of current smoker and
drinker (p <0.0001). The SDH group had the highest
body mass index and the most adverse lipid profile,
whereas the ISH group had the highest proportion of
DM, CKD, and CVD history. Across the three subtypes,
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the ISH group had the highest mean 10-yr predicted
ASCVD risk score (40.1% by PCE; 24.3% by KRPM),
followed by the SDH group (10.6% by PCE; 9.5% by KRPM),
then the IDH group (2.1% by PCE; 2.7% by KRPM).
Discussion
In this study of nationally representative samples, we
extended the conventional assay of hypertension preva-
lence by assessing its difference using the two contempor-
ary diagnostic criteria. An important advance of this study
was how we further examined the subtype composition
that attributed to overall differences, separately by sex and
age groups. Overall, the prevalence of all untreated hyper-
tension was markedly higher by the 2017 ACC/AHA
guideline due to the lowered BP cutoff, which was primar-
ily manifested through increase in IDH prevalence, par-
ticularly in younger population. This predominant make-
up of IDH is further highlighted by the considerable stag-
nancy in ISH prevalence despite the lowered SBP cutoff
and moderate increase in SDH prevalence, presumably
resulting from the lowered diastolic cutoff.
Our results are in accordance with the established BP
pathophysiology over lifespan. The natural trajectory of
BP increases until the fifth or sixth decade of life, subse-
quently followed by a gradual decline of DBP whilst a
continued elevation of SBP; such phenomena are im-
mune to demographics, treatment status, and physician
practices [29]. Consequently, such diverging course of
SBP and DBP supports observations [30, 31] noted in
Korean population, in which IDH was the most fre-
quently found among young participants, whereas ISH
was more commonplace in the older counterpart. Such
was also observed in Chinese population, where the age-
adjusted hypertension prevalence of total study population
was 20.9%, which was comprised of IDH, 4.44%; ISH,
3.30%; SDH, 4.11%; and the remainder, treated [32].
Moreover, the age-differential proportion of subtypes
among the treated individuals may also explain the high
proportion of IDH observed in our study. According to
the Korea Hypertension Fact Sheet 2018 [7], young adults
had substantially lower hypertension awareness, treat-
ment, and control rate compared to their older counter-
parts. Then, assuming a large proportion of SDH is likely
to be embodied by elderly population with higher likeli-
hood of treatment, hypertension proportion may be het-
erogeneous between untreated and treated individuals,
thereby explaining the pronounced IDH prevalence in our
data of untreated individuals.
Our findings also concur with the pattern of increased
hypertension prevalence in adherence to the 2017 ACC/
AHA guideline, reported in Muntner et al.’s assay of poten-
tial US population impact from the 2017 ACC/AHA guide-
line [33]. Consistent with our findings, the overall
hypertension prevalence was 31.9% (versus 25.9% in our
study) by the JNC 7 guidelines, with 13.7% elevation to
45.6% (versus 46.3%, likewise) by the 2017 ACC/AHA
guideline among untreated participants; such increase was
present for all age, sex, race/ethnicity, and CVD risk sub-
groups except those with a very low 10-year CVD risk (<
5%).
The differences in hypertension subtype prevalence by
the two guidelines were differentially manifested by age
distributions. Specifically, the majority of the added
prevalence originated from age 20–49 years qualifying as
IDH then as SDH with the lowered BP cutoff by the
2017 ACC/AHA guideline. This drastic growth in IDH
prevalence is of particular concern. Fundamentally, the
2017 ACC/AHA guideline’s shift to lowered BP cutoff
was based on evidence from epidemiologic studies [10,
11] and randomized trials [34–37]; they demonstrated
that even mildly elevated BP (defined as prehypertension
by the 2018 KSH guideline) would increase risk for adverse
heart-related outcomes, and lowering of SBP below 130
mmHg would reduce CVD risk. A previous meta-analysis
showed that lowering of usual SBP by 20-mmHg or DBP
by 10-mmHg was associated with halved risk for all stroke
and cerebral heart disease mortality, with indefinite
lower threshold [9]. However, the clinical significance
and utility of DBP for CVD risk prediction have been
recently pondered upon [16]. Previous findings merit
SBP as more robust and consistent BP component for
later cardiovascular risk, whereas DBP showed incon-
sistent association after adjustment for or stratification
by SBP [16]. Moreover, there are perplexities regarding
the validity of incorporating DBP threshold in defining
hypertension and in referring for initiation of pharma-
ceutical treatment [13, 38, 39], as most of the random-
ized trials’ eligibility criteria have historically been
centered around SBP [35, 36, 40].
Yet, despite diversified perspectives surrounding the
benefits of detecting and treating mildly elevated DBP in
young people (particularly in those without target organ
comorbidity or near-zero 10-year ASCVD risk), we re-
main reserved to ascertain its benign nature. Majority of
the aforementioned studies that examined the prospect-
ive association between BP and future CVD incidence
and risk have primarily, if not solely, included middle-
aged to elderly subjects, whom the likelihood of high
DBP is inevitably lower than that of SBP. Furthermore,
even if they had included younger population, the higher
10-year ASCVD risk levels embodied by older subjects
would dilute the relative risks presented in the younger
population. Evidence also shows that high DBP by the
2017 ACC/AHA guideline did have increased risk for fu-
ture CVD, after adjusting for age, sex, body mass index,
socioeconomic status, smoking history, statin use and
various competing comorbidity (hazards ratio = 1.12,
95% CI 1.05–1.19) [16]. Considering the trajectory and
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Fig. 1 Hypertension subtype prevalence according to the 2017 ACC/AHA and 2018 KSH guidelines in total population. Abbreviations: ACC/AHA,
American College of Cardiology/American Heart Association; BP, blood pressure; HTN, hypertension; IDH, isolated diastolic hypertension; ISH,
isolated systolic hypertension; KSH, Korean Society of Hypertension; SDH, systolic diastolic hypertension
Fig. 2 Hypertension subtype prevalence according to the 2017 ACC/AHA and 2018 KSH guidelines in male population. Abbreviations: ACC/AHA,
American College of Cardiology/American Heart Association; BP, blood pressure; HTN, hypertension; IDH, isolated diastolic hypertension; ISH,
isolated systolic hypertension; KSH, Korean Society of Hypertension; SDH, systolic diastolic hypertension
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associated risk of early onset hypertension are main-
tained until the later life, further studies are warranted
to narrow scope on young populations’ BP and ASCVD
risk level distributions for accurate assessment of their
absolute, relative, and population attributable risks [41,
42]. Lastly, the recently released European Society of
Cardiology/European Society of Hypertension (ESC/
ESH) guideline also appears in favor of stringent BP
control compared to its previous version by recommend-
ing drug treatment for high normal BP (130–139/85–89
mmHg) with high underlying CVD risk [43]. In the ab-
sence of long-term randomized trials on these subpopula-
tions and with established findings on prolonged
aftermath of hypertension diagnosed during young adult-
hood, our estimates pave epidemiological ground to ex-
plore potential risk of IDH in young age.
Our study has several notable strengths. To the extent
of our knowledge, this is the first study to examine all
hypertension and its subtype prevalence by the two con-
temporary guidelines embodying different diagnostic cri-
teria and to assess their differences in sex- and age-
specific manner. With KNHANES’ collection of wide
range and rich depth of information on nationally repre-
sentative samples, our findings can adequately capture
contemporary population health status across various
stages and types of hypertension. In addition, the exam-
iners have used standardized methods and validated
tools to minimize potential measurement bias and
errors.
Despite robust data source and meticulous examin-
ation, limitations exist in the inherent characteristics of
the study population and design. Since the KNHANES is
essentially composed of homogeneous Korean ethnicity,
extrapolation of our findings to different race should be
sought with consideration for distinctive population struc-
ture, healthcare system, and individual biology and health
behaviors. Moreover, since we have excluded participants
who are currently taking antihypertensive medication, our
results cannot be generalized irrespective of treatment sta-
tus, as the treatment initiation and adherence rate are
known to significantly differ by demographics [44]. In
terms of data collection, although we have adopted a
mean from consecutive measurements, the nature of sin-
gle-occasion BP measurements are subjected to variability.
Another potential source of misclassification bias may
arise from white coat hypertension, a condition in which
patients experience persistent high BP levels when they
are measured in clinical surrounding or at a presence
of physician [45]. Future studies using repeated and
sporadic measurements from both clinic and ambula-
tory settings are encouraged for more stable representation
of BP levels. Lastly, because the information regarding
demographics and health-related behaviors, including the
formal diagnosis of hypertension and frequency of antihy-
pertensive intake, were obtained via self-report, recall bias
cannot be ruled out.
Conclusions
In conclusion, changes in each hypertension subtype preva-
lence make differential contribution to the additionally clas-
sified cases according to the 2017 ACC/AHA guideline
compared to the 2018 KSH guideline, and the degree of
such contributions is distinguishable by sex and age.
Whereas the changes in ISH prevalence is, overall,
Fig. 3 Hypertension subtype prevalence according to the 2017 ACC/AHA and 2018 KSH guidelines in female population. Abbreviations: ACC/
AHA, American College of Cardiology/American Heart Association; BP, blood pressure; HTN, hypertension; IDH, isolated diastolic hypertension; ISH,
isolated systolic hypertension; KSH, Korean Society of Hypertension; SDH, systolic diastolic hypertension
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Table 3 Characteristics of study participants by stage 1 hypertension subtype according to the 2017 ACC/AHA guideline based on
2007–2017 KNHANES (n = 11,336)
Stage 1 hypertension by the 2017 ACC/AHA Guideline
Stage 1 IDH;
SBP <130 mmHg
and DBP ≥80 mmHg
Stage 1 ISH;
SBP ≥130mmHg and
DBP <80 mmHg
Stage 1 SDH;
SBP ≥130mmHg and
DBP ≥80 mmHg
p-value
(n = 8067) (n = 1289) (n = 1980)
% Study population 76.2 (75.2–77.2) 8.2 (7.6–8.8) 15.6 (14.8–16.4)
Male sex 67.5 (66.3–68.6) 44.1 (40.7–47.4) 58.6 (56.0–61.2) <0.0001
Age group, yrs <0.0001
20–29 17.4 (16.3–18.6) 6.9 (4.6–9.2) 11.1 (9.0–13.2)
30–39 25.3 (24.0–26.5) 3.6 (2.2–5.1) 12.6 (10.6–14.5)
40–49 29.1 (27.9–30.3) 7.1 (5.0–9.1) 20.6 (18.3–22.8)
50–59 20.9 (19.8–21.9) 19.4 (16.5–22.3) 31.1 (28.6–33.5)
60–69 5.9 (5.4–6.3) 27.3 (24.5–30.0) 17.2 (15.4–19.0)
70–79 1.3 (1.1–1.6) 28.4 (25.5–31.2) 6.6 (5.5–7.6)
80+ 0.2 (0.1–0.2) 7.3 (5.7–8.9) 0.9 (0.5–1.3)
Smoking status <0.0001
Non-smoker 42.9 (41.6–44.2) 59.0 (55.5–62.5) 50.7 (48.0–53.4)
Previous smoker 17.9 (16.8–18.9) 17.4 (14.9–20.0) 18.4 (16.2–20.5)
Current smoker 39.3 (37.9–40.6) 23.6 (20.5–26.6) 30.9 (28.5–33.4)
Alcohol intake <0.0001
Non-drinker 6.2 (5.6–6.8) 21.3 (18.7–23.8) 11.4 (9.8–12.9)
Former drinker 25.2 (24.0–26.3) 35.1 (31.8–38.4) 27.1 (24.8–29.4)
Current drinker 68.6 (67.4–69.8) 43.6 (40.2–47.0) 61.6 (58.9–64.2)
Regular exercise <0.0001
Yes 30.4 (29.0–31.8) 25.8 (22.3–29.3) 30.4 (27.8–33.0)
No 69.6 (68.2–71.0) 74.2 (70.7–77.7) 69.6 (67.0–72.2)
BMI, kg/m2 24.4 (24.3–24.5) 23.8 (23.5–24.0) 24.8 (24.6–25.0) <0.0001
Total cholesterol, mg/dL 195.7 (194.7–196.6) 192.4 (190.0–194.8) 199.6 (197.7–201.6) <0.0001
HDL cholesterol, mg/dL 49.2 (48.9–49.5) 46.8 (48.0–49.5) 49.2 (48.5–49.9) <0.0001
Triglyceride, mg/dL 158.9 (154.6–163.2) 136.2 (129.1–143.3) 165.3 (158.3–172.4) <0.0001
Lipid-lowering agent intake 2.2 (1.8–2.5) 7.5 (5.9–9.2) 3.7 (2.8–4.5) <0.0001
Fasting glucose, mg/dL 98.0 (97.4–98.6) 104.7 (102.9–106.5) 101.3 (100.1–102.5) <0.0001
GFR, ml/min/1.73 m2 97.6 (97.2–98.1) 87.9 (86.7–89.0) 94.2 (93.4–95.0) <0.0001
Diabetes mellitus 6.4 (5.7–7.0) 18.2 (15.5–20.8) 9.2 (7.7–10.7) <0.0001
Chronic Kidney Disease 0.5 (0.4–0.6) 5.1 (3.7–6.4) 1.3 (0.8–1.8) <0.0001
Mean 10-yr predicted CVD risk*
High risk,*%, PCE 2.1 (1.8–2.4) 40.1 (36.7–43.5) 10.6 (9.3–12.0) <0.0001
High risk, *%, KRPM 2.7 (2.3–3.0) 24.3 (21.6–27.0) 9.5 (8.1–10.9) <0.0001
History of CVD 3.1 (2.6–3.6) 11.2 (9.0–13.4) 5.4 (4.1–6.7) <0.0001
Values are presented as % or mean (95% confidence interval)
P-values are derived from analysis of variance (ANOVA) for multiple comparison across the three subtype groups
Abbreviations: ACC/AHA American College of Cardiology/American Heart Association, BMI Body mass index, CI Confidence interval, CKD Chronic kidney disease,
CVD Cardiovascular disease, GFR Glomerular filtration rate, HDL High-density lipoprotein, IDH Isolated diastolic hypertension, ISH Isolated systolic hypertension,
KRPM Korean Risk Prediction Model, KSH Korean Society of Hypertension, PCE Pooled Cohort Equation, SDH Systolic diastolic hypertension
*10-yr risk was calculated among adults without a history of CVD
*High risk defined as a 10-year predicted cardiovascular disease risk ≥10% or history of CVD
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negligible and moderate increases in SDH prevalence are
observed in middle-aged population, the marked increase
in IDH prevalence among young age groups highlights the
overall increase in all hypertension prevalence. Despite
seemingly-ameliorative 10-year ASCVD risk levels esti-
mated in young individuals, we currently lack prospective
data with sufficient time horizons to infer clinical implica-
tions of lowered systolic and diastolic cutoffs. Therefore, ir-
respective of the baseline risk, future epidemiological
studies should surveil subclinical ASCVD incidence and
clinical trials should investigate the benefits of long-term
primary prevention, specifically targeting the young popula-
tion. Until then, persistent and comprehensive BP manage-
ment should be sought, with discretion, but with tenacity,
regardless of degree of BP elevation in any age group.
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